Attached files

file filename
10-Q - FORM 10-Q - GALECTIN THERAPEUTICS INCd402747d10q.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A) - GALECTIN THERAPEUTICS INCd402747dex312.htm
EX-32.1 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 - GALECTIN THERAPEUTICS INCd402747dex321.htm
EX-10.3 - EMPLOYMENT AGREEMENT - GALECTIN THERAPEUTICS INCd402747dex103.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A) - GALECTIN THERAPEUTICS INCd402747dex311.htm
EXCEL - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCFinancial_Report.xls

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Galectin Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas A. McGauley, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 9, 2012      

/s/ Thomas A. McGauley

    Name:   Thomas A. McGauley
    Title:   Chief Financial Officer
      (principal financial and accounting officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Galectin Therapeutics Inc. and will be retained by Galectin Therapeutics Inc. and furnished to the Securities and Exchange Commission or its staff upon request.